Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hierarchically tumor-activated nanoCRISPR-Cas13a facilitates efficient microRNA disruption for multi-pathway-mediated tumor suppression.

Theranostics - 1 Jan 2023

Liu Xiaowei, Yang Suleixin, Wang Li, Wu Xinyue, Wang Xinxin, Ou Chunqing, Yang Jin, Song Linjiang, Zhou Shiyao, Wu Qinjie, Gong Changyang

Abstract excerpt

Rationale: CRISPR-Cas13a is an efficient tool for robust RNA knockdown with lower off-target effect, which may be a potentially powerful and safe tool for cancer gene therapy. However, therapeutic effect of current cancer gene therapy that targeting monogene was compromised by the multi-mutational signal pathway alterations of tumorigenesis. Methods: Here, hierarchically tumor-activated nanoCRISPR-Cas13a (CHAIN)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to MicroRNAs

Share to Mutation

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 37284454
DOI: 10.7150/thno.81776
PMCID: PMC10240819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hierarchically tumor-activated nanoCRISPR-Cas13a facilitates efficient microRNA disruption for multi-pathway-mediated tumor suppression.PMID 37284454Read ↗

Crispr Cas9 fluorine-containing PEI nanomedicine inhibits the growth of hepatocellular carcinoma cells by knocking out NEDD8-E2 conjugase UBC12 (UBE2M)Semantic proximity Read ↗

Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinomaSemantic proximity Read ↗

Turing miRNA Into Infinite Coordination Supermolecule: A General and Enabling Nanoengineering Strategy for Resurrecting Nuclear Acid TherapeuticsSemantic proximity Read ↗

Programmable Aptamer-Embedded Circular RNAs for Targeted Antigen-Presenting Cells ImmunotherapySemantic proximity Read ↗

Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-systemSemantic proximity Read ↗

Expression of a RAS degrader via synthetic nanocarrier-mediated mRNA delivery reduces pancreatic tumorsSemantic proximity Read ↗

Targeted epigenetic repression of oncogenic transcription factors via CRISPR/dCas9 locus-specific silencingSemantic proximity Read ↗

Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-system: In Silico and In Vitro StudySemantic proximity Read ↗

Sequentially Self-Assembled Supramolecular Nanocomplexes Enable Systemic Cas9 RNP Delivery and <i>In Vivo</i> Tumor Genome EditingSemantic proximity Read ↗

Sequentially Self-Assembled Supramolecular Nanocomplexes Enable Systemic Cas9 RNP Delivery and In Vivo Tumor Genome EditingSemantic proximity Read ↗

In vivo self-assembled siRNA: a new modality for combination therapy of ulcerative colitisSemantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.